SJ , - you are right , expectation should be lower
Post# of 144732
![](/images/icons/icon_smile.gif)
480 mil estimate was done predicting 20,000 patients in the first year and price of 24,000.00 per patients per year.
With the new price of 70,000.00 per patient per year ( and now they even talking 110,000.00 )
That will give us less than 7000 patients for the first year.
IMO , such a low number is not possible ...
They predicting for 2020 over 260 K patients with MDR2 , this will be about
180,000 patients CCR5 positive .
They predicting about 25,000 patients with MDR 3 , this will be about 17.500 patients CCR5 positive.
If those will be my patients all MDR2 I will put on Leronlimab so they don't progress to MDR3.
MDR3 people are much sicker already...
And for MDR 3 they have only Maraviroc and IV Ibalizumab ..
I will think most of this over 17,500 patients will like to try SC Leronlimab...
So whichever way we looking , 480 M is extremely conservative.
As for insurance diagnosis code I am not sure if it is different for resistant HIV with not resistant , I don't think so . I know when patient has AIDS code is different.
Anyway my first cousin is a surgeon , very often operating in the hospital , I just called and left him a message to call me back, and at any time if he see infectious disease to ask this Q.
I also will ask my best friend who is practicing internist in NJ the same Q , she should really know the answer.
I will do that this evening , now she has office hrs...
I will let you know the answer ...
![Like This Post](/images/thumb-up.png)
![Dislike This Post](/images/thumb-down.png)